TAK-915, a phosphodiesterase 2A inhibitor, ameliorates the cognitive impairment associated with aging in rodent models
Sign Up to like & getrecommendations! Published in 2019 at "Behavioural Brain Research"
DOI: 10.1016/j.bbr.2019.112192
Abstract: Changes in the cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) signaling are implicated in older people with dementia. Drugs that modulate the cAMP/cGMP levels in the brain might therefore provide new therapeutic options… read more here.
Keywords: associated aging; phosphodiesterase; cognitive impairment; tak 915 ... See more keywords